- Conditions
- Migraine
- Interventions
- DFN-15 Dose A (treatment A), DFN-15 Dose B (treatment B), Placebo (treatment C)
- Drug · Other
- Lead sponsor
- Dr. Reddy's Laboratories Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Long Beach, California • Santa Monica, California • Watertown, Massachusetts + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 988
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Post-ERCP Acute Pancreatitis
- Interventions
- Indomethacin, Lactated Ringer's Solution, Normal Saline, Placebo
- Drug
- Lead sponsor
- The Cooper Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Camden, New Jersey
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Lipid Metabolism Disorder, Metabolic Disease, Lipid Metabolism, Inborn Errors, Genetic Disease, Inborn, Hyperlipoproteinemias
- Interventions
- Obicetrapib, Placebo
- Drug
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 20
- States / cities
- Jonesboro, Arkansas • Toluca Lake, California • Sarasota, Florida + 17 more
- Conditions
- Coccidioidomycosis
- Interventions
- nikkomycin Z, Placebo
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Obesity
- Interventions
- Sitagliptin, Pegvisomant, Placebo, L-NMMA, Exendin 9-39
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Chronic Hepatitis C
- Interventions
- SOF, RBV, Placebo to match SOF, Placebo to match RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Coronado, California • Los Angeles, California + 40 more
- Conditions
- Hepatitis C Virus
- Interventions
- BMS-791325, Placebo, Peg-interferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 10
- States / cities
- Anaheim, California • Maywood, Illinois • Baltimore, Maryland + 6 more
- Conditions
- Recurrent Glioblastoma
- Interventions
- Dendritic Cell Tumor Cell Lysate Vaccine, Pembrolizumab, Placebo Administration, Poly ICLC
- Biological · Other · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- BMS-986036, Placebo (Matching with BMS-986036)
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- Not listed
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Anaheim, California • Los Angeles, California + 6 more
- Conditions
- Posttraumatic Headache, Posttraumatic Stress Disorder
- Interventions
- Group A active comparator, Group B active comparator, Group C Experimental, Group D Placebo Comparator
- Procedure · Drug · Combination Product + 1 more
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Bethesda, Maryland • Fort Bragg, North Carolina
- Conditions
- Infections, Bacterial
- Interventions
- Gepotidacin, Cimetidine, Rifampicin, Midazolam, Digoxin, Placebo matching to gepotidacin
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Pneumonia, Bacterial
- Interventions
- tigecycline, imipenem/cilastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Omaha, Nebraska • Morgantown, West Virginia
- Conditions
- Neoplasms, Breast
- Interventions
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Placebo, Aromatase inhibitor, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Trastuzumab
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 8
- States / cities
- Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more
- Conditions
- Type 2 Diabetes
- Interventions
- Placebo, Survodutide
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 81 more
- Conditions
- Psoriasis
- Interventions
- CP-690,550 Ointment 1, Vehicle 1, CP-690,550 Ointment 2, Vehicle 2
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 8
- States / cities
- Mobile, Alabama • Los Angeles, California • Orange Park, Florida + 4 more
- Conditions
- Renal Anemia
- Interventions
- AND017, Placebo
- Drug
- Lead sponsor
- Kind Pharmaceuticals LLC
- Industry
- Eligibility
- 20 Years to 74 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 7
- States / cities
- Northridge, California • Winter Park, Florida • Shreveport, Louisiana + 4 more
- Conditions
- Cirrhosis, Liver
- Interventions
- GI262570 0.5 mg, GI262570 1.0 mg, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 45 more
- Conditions
- Hypercholesteremia
- Interventions
- Gemcabene, Placebo
- Drug
- Lead sponsor
- NeuroBo Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Huntington Park, California + 19 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- JNJ-53718678 500 mg, JNJ-53718678 80 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 13
- States / cities
- Cerritos, California • Chula Vista, California • Garden Grove, California + 10 more
- Conditions
- Non-ischemic Dilated Cardiomyopathy
- Interventions
- allogeneic human mesenchymal stem cells (hMSCs), Placebo
- Biological · Other
- Lead sponsor
- Joshua M Hare
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 4
- States / cities
- Stanford, California • Miami, Florida • Louisville, Kentucky + 1 more
- Conditions
- Raynaud's Phenomenon Secondary to Connective Tissue Disease
- Interventions
- Vascana (0.9% nitroglycerin cream), Vehicle Cream (placebo)
- Drug
- Lead sponsor
- Covis Pharma S.à.r.l.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Multiple Locations, Pennsylvania
- Conditions
- Migraine, Acute Treatment of Migraine
- Interventions
- Rimegepant, Placebo, Sumatriptan
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,026 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 41
- States / cities
- Scottsdale, Arizona • Tempe, Arizona • San Francisco, California + 35 more
- Conditions
- COVID-19
- Interventions
- Danicopan, Placebo, Remdesivir
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Bakersfield, California • Fresno, California + 33 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Otamixaban, Placebo (for Otamixaban), UFH, Placebo (for UFH), Eptifibatide, Placebo (for Eptifibatide)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13,220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 107
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 82 more